Catherine Joseph1, Jyothsna Gattineni. 1. Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, Texas 75390-9063, USA.
Abstract
PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.
PURPOSE OF REVIEW: Complement mediated hemolytic uremic syndrome (aHUS) accounts for a significant proportion of non-shiga toxin HUS. The purpose of this review is to outline the pathophysiology, clinical features and therapeutic options for aHUS. RECENT FINDINGS: In the last decade, strides have been made in identifying several new disease-causing mutations in complement-regulating proteins. SUMMARY: Complement mediated HUS (aHUS) has a worse prognosis compared with shiga toxin mediated HUS, often resulting in end stage renal disease. Early identification of aHUS is crucial so that plasma therapy can be initiated. After renal transplantation, there is very high risk of disease recurrence and graft loss. Eculizumab and combined liver-kidney transplantation offer promise for improved prognosis.
Authors: Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi Journal: Blood Date: 2006-04-18 Impact factor: 22.113
Authors: P Warwicker; T H Goodship; R L Donne; Y Pirson; A Nicholls; R M Ward; P Turnpenny; J A Goodship Journal: Kidney Int Date: 1998-04 Impact factor: 10.612
Authors: Elena Goicoechea de Jorge; Claire L Harris; Jorge Esparza-Gordillo; Luis Carreras; Elena Aller Arranz; Cynthia Abarrategui Garrido; Margarita López-Trascasa; Pilar Sánchez-Corral; B Paul Morgan; Santiago Rodríguez de Córdoba Journal: Proc Natl Acad Sci U S A Date: 2006-12-20 Impact factor: 11.205
Authors: V Fremeaux-Bacchi; M-A Dragon-Durey; J Blouin; C Vigneau; D Kuypers; B Boudailliez; C Loirat; E Rondeau; W H Fridman Journal: J Med Genet Date: 2004-06 Impact factor: 6.318
Authors: Karen van Hoeve; Corinne Vandermeulen; Marc Van Ranst; Elena Levtchenko; Lambert van den Heuvel; Djalila Mekahli Journal: Eur J Pediatr Date: 2017-01-21 Impact factor: 3.183
Authors: Oscar Javier León Guerra; Ricardo Saul Galeano Rodríguez; William Javier Morales Camacho; Jessica Estefanía Plata Ortiz; María Alejandra Morales Camacho Journal: Rev Paul Pediatr Date: 2019-11-25
Authors: John Rathbone; Eva Kaltenthaler; Anna Richards; Paul Tappenden; Alice Bessey; Anna Cantrell Journal: BMJ Open Date: 2013-11-04 Impact factor: 2.692